Arch Biopartners Inc.
ACHFF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$59.1M
Close$
$-0.03
105.3% downside
Current Fair Value
105.3% downsideOvervalued by 105.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $59.10 Million |
|---|---|
| Enterprise Value | $61.83 Million |
| Earnings per Share | $-0.02 |
| Beta | 1.58 |
| Outstanding Shares | 67,926,334 |
Return
| Return on Equity | 70.89% |
|---|---|
| Return on Assets | -4937.88% |
| Return on Invested Capital | 64.84% |
Valuation & Multiples
| P/E Ratio | -20.47 |
|---|---|
| PEG | -21.31 |
| Price to Sales | - |
| Price to Book Ratio | -0.59 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -23.93 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.68 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.01
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
February 2, 2027
EPS Estimate
$-0.01
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Arch Biopartners Inc.
6 employees
CEO: Richard Gabriel Muruve
Arch Biopartners Inc. is a biotechnology company focused on developing innovative technologies with significant medical and commercial potential. Their primary endeavor involves advancing Metablok, a lead drug candidate designed to treat...